SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media shares are under pressure as traders connect the decline to Trumps reported record-low approval and approaching midterms, while also questioning the companys business fundamentals. Some see the selloff as a speculative buying opportunity, but bearish sentiment dominates.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a sharp selloff and mounting concern over its heavy debt, costly financing, and ability to fund AI infrastructure expansion. Bears see refinancing and dilution risks outweighing its AI demand and backlog, while bulls point to those growth prospects and dip buying; a bullish analyst call and ARK purchases have not quelled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is the dominant topic, with traders pointing to lockup-related share supply, reported insider selling and a TD Cowen price-target cut, alongside concerns about valuation and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are adding to positions.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff alongside other bitcoin miners is driving discussion, with traders pointing to financing and debt costs, higher rates, and weak sector sentiment. Bulls argue the Meta-backed AI data-center lease and bitcoin holdings offer longer-term support, while skeptics say those positives have not offset near-term risks or the stocks underperformance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anktivas FDA label expansion into papillary-only bladder cancer is the main catalyst, but IBRX has sold off despite the approval and positive trial updates. Bulls characterize the decline as a sell-the-news move or short pressure, while skeptics point to valuation, competition, and the need for revenue growth to support the companys expectations.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers prolonged share-price weakness is driving debate over whether robotaxi competition from Waymo and Tesla threatens its rides business, or whether that risk is overstated given its scale and cash generation. Some traders view the shares as undervalued and welcome the ezCater deal as a boost to delivery, while others remain frustrated by the stocks persistent underperformance.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians prolonged slide to fresh 52-week lows is driving discussion, with traders focused on concerns about cash burn, execution and the R2 production ramp ahead of Q3 earnings, despite stronger deliveries. Some are buying the dip and pointing to R2 progress and VW backing, while others question profitability and whether upcoming results can change sentiment.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and a lack of firm customer commitments. Traders debate whether the selloff is an overreaction or reflects real execution and cash-burn risks, with some expecting a rebound and others questioning whether NuScale can secure projects and deliver reactors.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the anticipated completion of Compass Pathways rolling FDA application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and the potential path toward approval and commercialization. Many traders see the regulatory milestone as a catalyst, while others are frustrated by the share-price weakness and uncertainty over the submission timeline and eventual FDA decision.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

EyePoints failed Phase 3 wet-AMD readout has intensified scrutiny of TKI-based treatments and weighed on OCUL, despite arguments that the setback removes a competitor. Traders disagree on whether the results cast doubt on AXPAXLIs prospects or are not comparable because OCUL uses a different molecule and has positive SOL-1 data; attention also centers on its pending NDA and the confirmatory SOL-R study.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaso Stock Surges 149% in a Year: What's Behind the Rally?

VASO is gaining from higher equipment deliveries, growing deferred commissions and a sharper healthcare focus, though partner dependence and margin pressures persist.

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose...

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the...

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the companys one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.This press release features multimedia. View the full...

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.

Here's Why DexCom (DXCM) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept...

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcoms global...

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setup

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue and earnings.</li><li>The company said elevated scrap and freight costs would continue to pressure margins in the near term, even as efficiency improvements are underway.</li><li>Some retail traders viewed the decline as a buying opportunity, calling the after-hours drop “uncalled for.”&nbsp;</li></ul>Dexcom shares slid 13% in after-hours trading on Thursday, as investors looked past a record third-quarter (Q3) profit and focused instead on rising costs and a cautious outlook for next year.The glucose monitoring company reported $1.21 billion in revenue for Q3, up 22% year over year, driven by strong demand across the U.S. and international markets. Net income jumped to $242.5 million, or $0.61 per share, its highest ever.Dexcom also raised its full-year revenue forecast to $4.63-$4.65 billion, representing around 15% growth. However, the company’s upbeat sales&nbsp;weren’t enough to offset concerns about profitability, as it said gross margins will remain near 61%, down about 170 basis points year over year.<h2 class="st-heading-2">Margin Pressure And Outlook</h2>The company acknowledged that elevated scrap rates and freight costs continued to eat into profits. Management said the hit was “roughly half and half” between manufacturing waste and shipping expenses, though both are expected to ease gradually in the coming quarters.Looking ahead, Dexcom projected double-digit revenue growth in 2026, but slightly below Wall Street’s expectations. The forecast does not yet include potential benefits from broader insurance coverage for type 2 diabetes patients, which the company said could provide upside later on.Dexcom added that its new 15-day G7 sensor, currently rolling out to users, will have a limited impact this year but should meaningfully boost margins and growth in 2026 once it gains wider reimbursement.<h2 class="st-heading-2">Growth Drivers Remain Intact</h2>Despite the market reaction, Dexcom’s underlying growth story remains strong. The company continues to expand its reach in the type 2 diabetes market, now covering nearly 6 million non-insulin patients in the U.S.International revenue grew 22%, led by strong momentum in France and Canada following new reimbursement coverage. Its consumer-focused continuous glucose monitor, Stelo, topped $100 million in sales within its first year, with plans to launch in more markets in 2026. Dexcom ended the quarter with over $3.3 billion in cash.<h2 class="st-heading-2">Stocktwits Traders Stay Bullish Despite Selloff</h2>On Stocktwits, retail sentiment for Dexcom was ‘extremely bullish’ amid a 921% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:959/126;" src="https://news.stocktwits-cdn.com/dxcm_ss_jpg_7ecd09626d.webp" alt="dxcm ss.jpg" width="959" height="126"><figcaption>DXCM sentiment and message volume as of October 30 | Source: Stocktwits</figcaption></figure>One user said the market reaction reflected disappointment that the company’s longtime executive, now CEO, had signaled that Wall Street’s expectations for 2026 growth were too high, while also acknowledging a slowdown in new patient starts.<stembedurl>https://stocktwits.com/freddycan/message/634416837</stembedurl>Another user said they hoped analysts would issue more bullish reports and raise price targets, describing the selloff as “uncalled for.”<stembedurl>https://stocktwits.com/longshortequities/message/634409824</stembedurl>A third user took the opposite stance, calling the pullback a buying opportunity.<stembedurl>https://stocktwits.com/Okadarlan/message/634408938</stembedurl><a href="https://stocktwits.com/symbol/DXCM">Dexcom’s stock</a> has declined 12% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Investors focused on Dexcom’s lower gross margin of 61.3%, down about 170 basis points year-over-year, despite record revenue and earnings.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$DXCM (Dexcom) shares fell 1.1% to close at $87.93 as rising Treasury yields and stronger-than-expected economic data pressured healthcare and tech names heading into Thursday's open.

Quassar Capital

$DXCM: eight Dexcom breach suits sit with six judges in San Diego, not yet consolidated. On Oct 14 one case moved to the first judge under the low-number rule. Breach still unconfirmed, nothing to claim. Open Class Actions.

Clam Clamwell

$DXCM: the Dexcom breach suits jumped from three to eight. Five more were filed Oct 13-14 in San Diego, all off the ShinyHunters listing Dexcom still has not confirmed. No class certified, nothing to claim. Open Class Actions.

$DXCM why do people trade at this level while it is mooning based on the data. beats me😂

YoBiDing

$DXCM: Published CONNECT trial data showed Dexcom's G7 cut A1C by 1.6% and added five daily hours in the target range.

Briefing.com

$DXCM case watch: three overlapping breach suits in San Diego may consolidate before one judge. All rest on a ShinyHunters listing with no sample files posted, and Dexcom has not confirmed a breach. Nothing to claim. Open Class Actions.

$DXCM 
There’s no reason this should be under $90, I mean really, even seeking Alpha has a strong buy so wtf 🤦🏼‍♀️￼

Feed

News

Sentiment

Earnings

Fundamentals

Info

DXCM Dexcom Inc

Fundamentals

Latest DXCM News